home / stock / alxo / alxo news

ALXO News and Press, ALX Oncology Holdings Inc. From 11/02/20

Stock Information
Company Name: ALX Oncology Holdings Inc.
Stock Symbol: ALXO
Market: NASDAQ
Website: alxoncology.com
Menu
ALXO ALXO Quote ALXO Short ALXO News ALXO Articles ALXO Message Board
Get ALXO Alerts

News, Short Squeeze, Breakout and More Instantly...
ALXO - ALX Oncology Announces November 2020 Virtual Investor Conference Participation

BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President an...
ALXO - Arcturus Progresses ARCT-810 Trial, And Other News: The Good, Bad And Ugly Of Biopharma

Arcturus Therapeutics progresses ARCT-810 trial, inks new ARCT-021 collaboration. ALX Oncology provides updates for ALX148 study in myelodysplastic syndrome. Rubius Therapeutics reports positive data for HPV-positive cancers therapy. For further details see: Arcturus Pro...

ALXO - Dosing underway for ALX Oncology's ALX148 in mid-stage blood cancer study

ALX Oncology (ALXO) has dosed the first patient in the Phase 1/2 ASPEN-02 study evaluating the combination of ALX148 with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome ((MDS)).The Phase 1 part of the study is expected to characterize the safety of AL...

ALXO - ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

BURLINGAME, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the Phase...
ALXO - ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

BURLINGAME, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that ALX148 clinical results have been selec...

ALXO - ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board

BURLINGAME, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the formation ...

ALXO - ALX Oncology Is A Promising CD47 Targeting Biotech With Massive Potential

ALX Oncology enters into clinical trial collaboration agreement with Merck to use ALX148 in combination with Keytruda to treat patients with head and neck squamous cell carcinoma. It was shown that patients treated with the combination of ALX148 and Keytruda had achieved a 40% objecti...
ALXO - ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer

BURLINGAME, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- ALX Oncology (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial collaboration with Merck, known as MSD outside the Un...

ALXO - ALX Oncology to join the Rusell 2000 and Rusell 3000 indexes

ALX Oncology (NASDAQ: ALXO )   to join the small cap Russell 2000 index and Russell 3000 index, effective after the U.S. stock market opens on September 18. More news on: ALX Oncology Holdings Inc., Healthcare stocks news Read more ...

ALXO - ALX Oncology Added to Russell 2000® and 3000® Indexes

BURLINGAME, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it will be added as a member of the Rus...
Previous 10 Next 10